1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

Lipum: Focusing on financing phase II

  • The clinical study report published
  • A financing rpund expected in Q2
  • Our model suggests a fair value of SEK 16.29 per share

The clinical study report of Lipum’s phase I study with SOL-116 was published in April. In line with the topline data, the complete findings strongly support further clinical development of the drug candidate. The company is now planning the phase II study in rheumatoid arthritis (RA), expected to start in Q1 2026. Essential for the development is securing the funding. By the end of Q1, Lipum’s cash holdings amounted to MSEK 4.26. We anticipate a rights issue being announced shortly.
Read the full report here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2025-04-28, kl 12:40
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!